Display options
Cite
Dudek D, Heba G, Legutko J, et al. Effect of early statin and selective cyclooxygenase-2 inhibitor therapy on C-reactive protein level after percutaneous coronary angioplasty in unstable angina. EuroIntervention. 2005;1(3):315-20
Dudek, D., Heba, G., Legutko, J., Chyrchel, M., Rakowski, T., Kaluza, G. L., & Dubiel, J. S. (2005). Effect of early statin and selective cyclooxygenase-2 inhibitor therapy on C-reactive protein level after percutaneous coronary angioplasty in unstable angina. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 1(3), 315-20.
Dudek, Dariusz, et al. "Effect of early statin and selective cyclooxygenase-2 inhibitor therapy on C-reactive protein level after percutaneous coronary angioplasty in unstable angina." EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology vol. 1,3 (2005): 315-20.
Dudek D, Heba G, Legutko J, Chyrchel M, Rakowski T, Kaluza GL, Dubiel JS. Effect of early statin and selective cyclooxygenase-2 inhibitor therapy on C-reactive protein level after percutaneous coronary angioplasty in unstable angina. EuroIntervention. 2005 Nov;1(3):315-20. PMID: 19758923.
Copy Download .nbib Format: NLM
Share it on

EuroIntervention. 2005 Nov;1(3):315-20.

Effect of early statin and selective cyclooxygenase-2 inhibitor therapy on C-reactive protein level after percutaneous coronary angioplasty in unstable angina.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Dariusz Dudek, Grzegorz Heba, Jacek Legutko, Michal Chyrchel, Tomasz Rakowski, Grzegorz L Kaluza, Jacek S Dubiel

Affiliations

  1. Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.

PMID: 19758923

Abstract

AIMS: We evaluated the effect of cyclooxygenase-2 inhibitor rofecoxib added to atorvastatin, initiated immediately after percutaneous coronary angioplasty (PCI), on C-reactive protein (CRP) and interleukin-6 (IL-6) in patients with unstable angina (UA).

METHODS AND RESULTS: Sixty patients were prospectively randomized to receive: (A) 10 mg atorvastatin or (B) 40mg atorvastatin or (C) atorvastatin 40 mg plus rofecoxib 12.5 mg. Treatment was continued for 6 months. CRP and IL-6 levels increased within 48 hours after PCI in all groups, in comparison with A and B, a more pronounced decrease in CRP (mg/l) and IL-6 (pg/ml) levels at 3- and 6-month follow-up was present in C: CRP at 6 months: 0.76 vs. 1.92 vs. 0.11, p<0.05; IL-6 at 6 months: 0.02 vs. 0.04 vs. 0.01, p<0.05. At 6-month follow-up the reduction in CRP level occurred in 70% of subjects with CRP higher than median (3.6mg/l) at baseline vs. 15% of patients with CRP lower than median (p<0.041).

CONCLUSION: After PCI in UA, cyclooxygenase-2 inhibitor rofecoxib added to atorvastatin reduced CRP and IL-6 levels more profoundly than atorvastatin alone at 3- and 6-month after intervention. In the group receiving combined therapy, reduction in CRP levels was more frequently observed in patients with higher CRP at baseline.

Publication Types